Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
443231 | Journal of Molecular Graphics and Modelling | 2016 | 13 Pages |
•Description of a pharmacophore for bradykinin B1 antagonism.•The pharmacophore was obtained from the B1 receptor constructed by homology modeling and refined by molecular dynamics.•On the model constructed five known selective antagonists were docked.•Analysis of the superimposed ligands permitted to define a pharmacophore.•The pharmacophore hypothesis was used to discover new compounds by in silico screening.
Bradykinin (BK) is a nonapeptide involved in several pathophysiological conditions including among others, septic and haemorrhagic shock, anaphylaxis, arthritis, rhinitis, asthma, inflammatory bowel disease. Accordingly, BK antagonists have long been sought after for therapeutic intervention. Action of BK is mediated through two different G-protein coupled receptors known as B1 and B2. Although there are several B1 antagonists reported in literature, their pharmacological profile is not yet optimal so that new molecules need to be discovered. In the present work we have constructed an atomistic model of the B1 receptor and docked diverse available non-peptide antagonists in order to get a deeper insight into the structure-activity relationships involving binding to this receptor. The model was constructed by homology modeling using the chemokine CXC4 and bovine rhodopsin receptors as template. The model was further refined using molecular dynamics for 600 ns with the protein embedded in a POPC bilayer. From the refinement process we obtained an average structure that was used for docking studies using the Glide software. Antagonists selected for the docking studies include Compound 11, Compound 12, Chroman28, SSR240612, NPV-SAA164 and PS020990. The results of the docking study underline the role of specific receptor residues in ligand binding. The results of this study permitted to define a pharmacophore that describes the stereochemical requirements of antagonist binding, and can be used for the discovery of new compounds.
Graphical abstractFigure optionsDownload full-size imageDownload high-quality image (98 K)Download as PowerPoint slide